P

Prostatype Genomics AB
STO:PROGEN

Watchlist Manager
Prostatype Genomics AB
STO:PROGEN
Watchlist
Price: 9.25 SEK -4.64% Market Closed
Market Cap: 47.6m SEK
Have any thoughts about
Prostatype Genomics AB?
Write Note

Prostatype Genomics AB
Cash & Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Prostatype Genomics AB
Cash & Cash Equivalents Peer Comparison

Comparables:
BIOG B
BONEX
VITR
SOBI
BIOA B

Competitive Cash & Cash Equivalents Analysis
Latest Figures & CAGR of Competitors

Company Cash & Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
P
Prostatype Genomics AB
STO:PROGEN
Cash & Cash Equivalents
kr2.7m
CAGR 3-Years
-45%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Biogaia AB
STO:BIOG B
Cash & Cash Equivalents
kr1.5B
CAGR 3-Years
2%
CAGR 5-Years
40%
CAGR 10-Years
N/A
Bonesupport Holding AB
STO:BONEX
Cash & Cash Equivalents
kr153.2m
CAGR 3-Years
-12%
CAGR 5-Years
3%
CAGR 10-Years
N/A
Vitrolife AB
STO:VITR
Cash & Cash Equivalents
kr925m
CAGR 3-Years
-42%
CAGR 5-Years
9%
CAGR 10-Years
23%
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
Cash & Cash Equivalents
kr594m
CAGR 3-Years
41%
CAGR 5-Years
-11%
CAGR 10-Years
0%
BioArctic AB
STO:BIOA B
Cash & Cash Equivalents
kr611.6m
CAGR 3-Years
-15%
CAGR 5-Years
-8%
CAGR 10-Years
N/A

See Also

What is Prostatype Genomics AB's Cash & Cash Equivalents?
Cash & Cash Equivalents
2.7m SEK

Based on the financial report for Dec 31, 2023, Prostatype Genomics AB's Cash & Cash Equivalents amounts to 2.7m SEK.

What is Prostatype Genomics AB's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 3Y
-45%

Over the last year, the Cash & Cash Equivalents growth was -44%. The average annual Cash & Cash Equivalents growth rates for Prostatype Genomics AB have been -45% over the past three years .

Back to Top